Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients

Leukemia

Volumn 28, Issue 4, 2014, Pages 967-970

  Visani, G ^a   Ferrara, F ^b   Di Raimondo, F ^c   Loscocco, F ^a   Sparaventi, G ^a   Paolini, S ^d   Fuligni, F ^d   Gazzola, A ^d   Rossi, M ^d   Laginestra, M A ^d   Caraci, M R ^b   Riccardi, C ^e   Rocchi, M ^d   Visani, A ^d   Pileri, S A ^d   Piccaluga, P P ^d   Isidori, A ^a  

^a AORMN   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; LENALIDOMIDE; TIPIFARNIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART FAILURE; AGED; CLINICAL ARTICLE; COMPLETE REMISSION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE; LIVER FUNCTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROSPECTIVE STUDIES; REMISSION INDUCTION; THALIDOMIDE;

EID: 84898427136     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.31     Document Type: Letter

References (15)

1. Estey EH. How to manage high-risk acute myeloid leukemia. Leukemia 2012; 26: 861-869.
2. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28: 4919-4925.
3. Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN et al. A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011; 117: 1828-1833.
4. Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012; 26: 893-901.
5. Pollyea DA, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica 2013; 98: 591-596.
6. Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN et al. A phase I study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia 2013; 27: 725-728.
7. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute: Bethesda, MD, 2006. Available at http://ctep.info.nih.gov/reporting/ctc.html.
8. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
9. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
10. Isidori A, Venditti A, Maurillo L, Buccisano F, Loscocco F, Manduzio P et al. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. Expert Rev Hematol 2013; 6: 767-784.
11. Scherman E, Malak S, Perot C, Gorin NC, Rubio MT, Isnard F. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype. Leukemia 2012; 26: 822-824.
12. Platzbecker U, Germing U. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? Leukemia 2013; 27: 1813-1819.
13. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas. Results of a phase 3 diagnostic accuracy study. J Clin Oncol 2013; 31: 3019-3025.
14. The Cancer Genome Atlas Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
15. Theilgaard-Mönch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 2011; 25: 909-920.